zanubrutinib · Brukinsa

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
Product first approved 2019FDA label
JP
  • Treatment of chronic lymphocytic leukemia (including small lymphocytic lymphoma), Waldenström's macroglobulinemia, and lymphoplasmacytic lymphoma
Product first approved 2024PMDA
EU
  • Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). Brukinsa in combination with obinutuzumab is indicated for the treatment of...
Product first approved 2021EMA
CN
  • Adult patients with relapsed/refractory mantle cell lymphoma who have received at least one prior therapy
Product first approved 2020biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Chronic Lymphocytic Leukemia
Follicular Lymphoma
NCT05100862 · BeOne Medicines
2022-03-10 – 2030-06 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Mantle Cell Lymphoma
NCT05164770 · Shandong Provincial Hospital
2021-03-01 – 2024-12-31 · High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT06522555 · Ruijin Hospital
2024-07-29 – 2029-08-10 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05735834 · International Extranodal Lymphoma Study Group (IELSG)
2024-05-21 – 2029-05 · Splenic Marginal Zone Lymphoma
What this study did
NCT04170283 · BeOne Medicines
2020-01-16 – 2026-12-31 · B-cell Malignancies
What this study did
NCT05179733 · Ruijin Hospital
2022-03-02 – 2025-12-25 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05320575 · Beijing Friendship Hospital
2022-02-01 – 2023-08-01 · HLH
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05707377 · BeOne Medicines
2023-04-17 – 2027-10 · Primary Membranous Nephropathy
What this study did
Phase 2 (138)
Chronic Lymphocytic Leukemia
NCT07739459 · The Lymphoma Academic Research Organisation
2026-12 – 2032-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06839053 · Fred Hutchinson Cancer Center
2025-06-02 – 2032-07-01 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT06544785 · PETHEMA Foundation
2024-09-02 – 2032-05-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07671378 · The First Affiliated Hospital with Nanjing Medical University
2026-06-01 – 2030-12-31 · CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT06367374 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-30 – 2030-07-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06849713 · Massachusetts General Hospital
2025-05-16 – 2030-03-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
What this study did
NCT07674810 · M.D. Anderson Cancer Center
2026-12-31 – 2029-04-30 · Chronic Lymphocytic Leukemia
What this study did
NCT05168930 · Dana-Farber Cancer Institute
2022-02-18 – 2028-10-28 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT07812246 · City of Hope Medical Center
2027-08-04 – 2028-08-13 · Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT07003464 · The First Hospital of Jilin University
2025-06-15 – 2028-06-01 · Chronic Lymphocytic Leukemia
What this study did
NCT06958705 · The First Affiliated Hospital with Nanjing Medical University
2025-12-01 – 2028-02-01 · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
What this study did
NCT07734038 · Kerry Rogers
2026-09-16 – 2027-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05650723 · Weill Medical College of Cornell University
2023-05-08 – 2027-12 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT07271667 · Curis, Inc.
2026-04-23 – 2027-11 · Chronic Lymphocytic Leukemia, B-cell Malignancies
What this study did
NCT05718869 · City of Hope Medical Center
2023-05-18 – 2027-07-27 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04458610 · M.D. Anderson Cancer Center
2020-05-26 – 2027-05-26 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT03824483 · Memorial Sloan Kettering Cancer Center
2019-02-22 – 2027-02 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
What this study did
NCT05873712 · Aseel Alsouqi
2023-07-28 – 2026-12-31 · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
What this study did
NCT04116437 · BeiGene
2019-10-15 – 2026-01-09 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT05287984 · Institute of Hematology & Blood Diseases Hospital, China
2022-03-22 – 2024-11-29 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
What this study did
NCT03206918 · BeiGene
2017-03-09 – 2020-09-10 · Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
What this study did
Follicular Lymphoma
NCT06492837 · Fondazione Italiana Linfomi - ETS
2024-10-23 – 2033-09-15 · Follicular Lymphoma
What this study did
NCT06563596 · Reid Merryman, MD
2025-01-21 – 2032-03-01 · Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
What this study did
NCT07299149 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-25 – 2030-12-25 · Follicular Lymphoma
What this study did
NCT06918015 · Zhejiang Cancer Hospital
2025-05-01 – 2030-05-01 · BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
What this study did
NCT07505849 · KeshuZhou
2026-03-23 – 2030-03-23 · Follicular Lymphomas
What this study did
NCT07418190 · The First Affiliated Hospital with Nanjing Medical University
2026-02-01 – 2029-12-31 · Relapsed/Refractory Follicular Lymphoma
What this study did
NCT06474481 · Tianjin Medical University Cancer Institute and Hospital
2024-07 – 2029-12 · FL
What this study did
NCT05890352 · SWOG Cancer Research Network
2023-09-26 – 2029-12 · Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
What this study did
NCT07550855 · Sun Yat-sen University
2026-09-01 – 2029-09-30 · Follicular Lymphoma (FL)
What this study did
NCT06350318 · H. Lee Moffitt Cancer Center and Research Institute
2024-04-19 – 2029-03 · Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
What this study did
NCT06959732 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-01-01 – 2027-12-31 · Follicular Lymphoma ( FL)
What this study did
NCT05389293 · Memorial Sloan Kettering Cancer Center
2022-05-27 – 2027-12 · Follicular Lymphoma, Lymphoma
What this study did
NCT06553352 · The First Affiliated Hospital of Xiamen University
2024-03-31 – 2027-08-31 · Follicular Lymphoma, Newly Diagnosed
What this study did
NCT06471738 · Chinese PLA General Hospital
2024-07-10 – 2027-06-01 · Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT06549335 · Ruijin Hospital
2024-12-01 – 2026-12-31 · Follicular Lymphoma
What this study did
NCT03520920 · BeiGene
2018-01-04 – 2020-08-28 · Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
What this study did
Mantle Cell Lymphoma
NCT06558604 · The Lymphoma Academic Research Organisation
2025-02-21 – 2032-03 · Lymphoma, Mantle-Cell
What this study did
NCT07341191 · Canadian Cancer Trials Group
2026-08-24 – 2030-12-31 · Mantle Cell Lymphoma
What this study did
NCT06427213 · Henan Cancer Hospital
2024-05-20 – 2029-12-30 · Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
What this study did
NCT07261163 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-20 – 2029-07-31 · Mantle Cell Lymphoma
What this study did
NCT06504199 · Institute of Hematology & Blood Diseases Hospital, China
2024-07-18 – 2028-12-31 · Mantle Cell Lymphoma
What this study did
NCT05635162 · University College, London
2024-05-17 – 2028-10 · Mantle Cell Lymphoma
What this study did
NCT07799220 · Memorial Sloan Kettering Cancer Center
2026-12 – 2028-09 · Mantle Cell Lymphoma
What this study did
NCT06341556 · Fudan University
2024-05-24 – 2028-06 · Mantle Cell Lymphoma, Maintenance Therapy
What this study did
NCT06255704 · Shanxi Province Cancer Hospital
2024-03-15 – 2027-12-01 · Mantle Cell Lymphoma
What this study did
Phase 1/2 (8)
Chronic Lymphocytic Leukemia
NCT07052695 · Inhye Ahn
2025-11-24 – 2032-12-31 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
What this study did
NCT06697184 · BeOne Medicines
2025-01-23 – 2032-11-30 · Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
What this study did
NCT04282018 · BeiGene
2020-04-29 – 2024-08-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Advanced Solid Tumor
What this study did
Mantle Cell Lymphoma
NCT06029309 · Alvaro Alencar, MD
2024-05-03 – 2032-05-01 · Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT06634589 · BeOne Medicines
2024-11-27 – 2029-12-02 · B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
What this study did
NCT06375733 · Genfleet Therapeutics (Shanghai) Inc.
2024-03-20 – 2026-12-31 · Large B-cell Lymphoma
What this study did
NCT04172246 · BeiGene
2020-01-29 – 2025-06-30 · Mature B-cell Malignancies
What this study did
Phase 1 (22)
Chronic Lymphocytic Leukemia
NCT06859008 · City of Hope Medical Center
2025-08-25 – 2029-01-31 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
What this study did
NCT06735664 · City of Hope Medical Center
2025-08-14 – 2027-12-13 · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
What this study did
NCT06547944 · Institute of Hematology & Blood Diseases Hospital, China
2024-01-01 – 2026-12-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
What this study did
NCT05665530 · Prelude Therapeutics Incorporated
2023-09-12 – 2026-01-21 · Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
What this study did
NCT02914938 · MEI Pharma, Inc.
2016-10 – 2023-03-29 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL)
What this study did
Follicular Lymphoma
NCT04850495 · Yazeed Sawalha
2021-11-16 – 2026-12-15 · Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
Mantle Cell Lymphoma
NCT07548255 · Ruijin Hospital
2026-04-20 – 2029-03-01 · Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
What this study did
Other / comorbidity
NCT06824701 · University of Utah
2025-09-12 – 2033-01 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
NCT06730542 · Juan P. Alderuccio, MD
2025-04-17 – 2030-04-30 · CNS Lymphoma
What this study did
NCT04277637 · BeOne Medicines
2020-03-24 – 2027-05-31 · Mature B-Cell Malignancies
What this study did
NCT04436107 · BeiGene
2020-09-11 – 2024-03-28 · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT05767398 · BeiGene
2023-03-07 – 2023-04-28 · Healthy Volunteers
What this study did
NCT05547399 · BeiGene
2022-06-07 – 2022-12-07 · Healthy Volunteers
What this study did
NCT04551963 · BeiGene
2020-11-15 – 2022-02-21 · B-cell Malignancies
What this study did
NCT02795182 · BeiGene
2016-06-29 – 2020-12-18 · Lymphoma, Leukemia
What this study did
NCT04470908 · BeiGene
2020-07-29 – 2020-11-10 · Healthy, Male
What this study did
NCT02569476 · BeiGene
2016-01-13 – 2020-09-02 · B-cell Lymphoid Malignancies
What this study did
NCT03189524 · BeiGene
2016-07-05 – 2020-08-26 · B-cell Lymphoma
What this study did
NCT03465059 · BeiGene
2018-05-30 – 2018-10-19 · Hepatic Insufficiency & Healthy Subjects
What this study did
NCT03561298 · BeiGene
2018-06-07 – 2018-07-02 · Healthy Subjects
What this study did
NCT04163523 · BeiGene
2016-05-25 – 2016-07-21 · Healthy Volunteers
What this study did
Phase 4 (4)
Other / comorbidity
NCT07474961 · Anne Louise Tølbøll Sørensen
2027-03 – 2036-12 · Waldenstrom Macroglobulinaemia, Multiple Myeloma
What this study did
NCT07169331 · BeiGene
2025-10-17 – 2028-10-31 · Waldenström's Macroglobulinemia
What this study did
NCT07270835 · The First Affiliated Hospital of Soochow University
2025-11-01 – 2027-08 · Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
What this study did
MACE and BTK Inhibitorsnot yet recruiting
NCT07923162 · University Hospital, Caen
2026-12-01 – 2027-03-01 · Hematologic Cancer, MACE, BTK Inhibitors
What this study did
Early phase / not applicable (6)
Follicular Lymphoma
NCT07126678 · The First Affiliated Hospital with Nanjing Medical University
2025-07-15 – 2028-12-30 · Follicular Lymphoma, Treatment Naive
What this study did
Other / comorbidity
NCT07299331 · Zhengzhou University
2026-01-01 – 2031-04-30 · Marginal Zone Lymphoma(MZL)
What this study did
NCT06942507 · Peking Union Medical College Hospital
2025-05-01 – 2029-04-30 · Waldenström's Macroglobulinemia (WM)
What this study did
NCT06445257 · Huai'an First People's Hospital
2023-09-15 – 2026-04-30 · Primary Central Nervous System Lymphoma
What this study did
NCT05117814 · Peking University People's Hospital
2021-09 – 2025-07 · CNS Lymphoma
What this study did
NCT05797948 · The First Affiliated Hospital of Soochow University
2022-07-01 – 2024-06-30 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Mantle Cell Lymphoma
NCT07377578 · Guangzhou Lupeng Pharmaceutical Company LTD.
2026-02-05 – 2033-01-30 · Mantle Cell Lymphoma
What this study did
NCT04662255 · Loxo Oncology, Inc.
2021-04-08 – 2030-06 · Lymphoma, Mantle-Cell
What this study did
Phase 2 (1)
Other / comorbidity
NCT04840602 · National Cancer Institute (NCI)
2022-01-05 – 2028-03-31 · Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Chronic Lymphocytic Leukemia
NCT07321652 · Alliance for Clinical Trials in Oncology
2026-04-30 – 2038-09-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
What this study did
Mantle Cell Lymphoma
Phase 2 (3)
Chronic Lymphocytic Leukemia
NCT06520098 · VA Office of Research and Development
2025-10-01 – 2030-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06637501 · BeOne Medicines
2024-11-14 – 2029-09 · Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT06695013 · Ruijin Hospital
2024-11-20 – 2027-03-20 · B-NHL, CART Therapy
What this study did
Phase 1 (1)
Chronic Lymphocytic Leukemia
NCT03666000 · Imugene Limited
2019-03-11 – 2027-06 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Mantle Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zanubrutinib (Brukinsa): this drugApprovedSmall moleculeBTKWeak signal
NCT04002297: Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01).
NCT03206970: Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results).
AcalabrutinibApprovedSmall moleculeBTKWeak signal
NCT02213926: Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants
BortezomibApprovedSmall moleculeProteasomenot yet gradedNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
Rilzabrutinib
Approved(overall)
Small moleculeBTK
Reliable signal(overall)
No reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)ApprovedSmall moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(103 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Brukinsa (zanubrutinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
November 2026 (1)
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2026-11 · NCT06669143 · CT.gov ↗
What to watch
December 2026 (11)
Phase 2Diffuse Large B Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2026-12 · NCT06594432 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06549335 · CT.gov ↗
What to watch
Phase 2Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2026-12-01 · NCT06561347 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06471738 · CT.gov ↗
What to watch
Phase 1/2Large B-cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06375733 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT05873712 · CT.gov ↗
What to watch
Phase 2Monoclonal Gammopathy of Uncertain SignificanceActive not recruiting
Est. primary completion 2026-12-31 · NCT05939037 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06504199 · CT.gov ↗
What to watch
Phase 2Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active not recruiting
Est. primary completion 2026-12-31 · NCT06647732 · CT.gov ↗
What to watch
Phase 2LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06563505 · CT.gov ↗
What to watch
Phase 3B-cell MalignanciesActive not recruiting
Est. primary completion 2026-12-31 · NCT04170283 · CT.gov ↗
What to watch
2027 (30)
February 2027 (3)
Phase 2Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04515238 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT03824483 · CT.gov ↗
What to watch
Phase 4Hematologic Cancer, MACE, BTK InhibitorsNot yet recruiting
Est. primary completion 2027-02-01 · NCT07923162 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT05650723 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-03-31 · NCT07012980 · CT.gov ↗
What to watch
April 2027 (3)
Phase 4Hemophagocytic Lymphohistiocytosis, B Cell LymphomaRecruiting
Est. primary completion 2027-04 · NCT07270835 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-04-30 · NCT07674810 · CT.gov ↗
What to watch
Early phase / not applicableWaldenström's Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2027-04-30 · NCT06942507 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-26 · NCT04458610 · CT.gov ↗
What to watch
Phase 1Mature B-Cell MalignanciesActive not recruiting
Est. primary completion 2027-05-31 · NCT04277637 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2B-cell Non Hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT06646666 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07003464 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-06-30 · NCT06959732 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-27 · NCT05718869 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-31 · NCT07261163 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Richter TransformationRecruiting
Est. primary completion 2027-08 · NCT04271956 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2/3Primary Membranous NephropathyActive not recruiting
Est. primary completion 2027-10 · NCT05707377 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib, Lenalidomide, Frail ElderlyRecruiting
Est. primary completion 2027-10-01 · NCT07839247 · CT.gov ↗
What to watch
Phase 2Primary Intraocular LymphomaRecruiting
Est. primary completion 2027-10-30 · NCT06973811 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-11 · NCT07271667 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-11-01 · NCT06136351 · CT.gov ↗
What to watch
December 2027 (9)
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2027-12 · NCT06474481 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-12 · NCT05389293 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06958705 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-13 · NCT06735664 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT06427213 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07405255 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07671378 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07734038 · CT.gov ↗
What to watch
2028 (29)
January 2028 (1)
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)Not yet recruiting
Est. primary completion 2028-01-01 · NCT06646211 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory CancerRecruiting
Est. primary completion 2028-02 · NCT05681195 · CT.gov ↗
What to watch
Phase 2Diffuse Large B Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2028-02-29 · NCT07371923 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT06849713 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-03-30 · NCT07550855 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-04-28 · NCT07299149 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT06803693 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-05 · NCT06558604 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-05-01 · NCT06029309 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-05-01 · NCT06918015 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Waldenström Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2028-06-30 · NCT07259122 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2028-07 · NCT05100862 · CT.gov ↗
What to watch
Early phase / not applicableFollicular LymphomaRecruiting
Est. primary completion 2028-07-15 · NCT07126678 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT06839053 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-08-10 · NCT06522555 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-08-13 · NCT07812246 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-09 · NCT07799220 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2028-09-15 · NCT06492837 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-10 · NCT05635162 · CT.gov ↗
What to watch
Phase 4Waldenström's MacroglobulinemiaActive not recruiting
Est. primary completion 2028-10-31 · NCT07169331 · CT.gov ↗
What to watch
December 2028 (9)
Phase 2MCLRecruiting
Est. primary completion 2028-12 · NCT06463691 · CT.gov ↗
What to watch
Phase 1/2B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell LymphomaRecruiting
Est. primary completion 2028-12-02 · NCT06634589 · CT.gov ↗
What to watch
Phase 2Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07315373 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2028-12-31 · NCT06547866 · CT.gov ↗
What to watch
Phase 2Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPNRecruiting
Est. primary completion 2028-12-31 · NCT07165769 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Recruiting
Est. primary completion 2028-12-31 · NCT07514169 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2028-12-31 · NCT07608978 · CT.gov ↗
What to watch
Phase 2Hairy Cell Leukemia, Hairy Cell Leukemia VariantEnrolling by invitation
Est. primary completion 2028-12-31 · NCT07690761 · CT.gov ↗
What to watch
2029 (18)
January 2029 (3)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-01 · NCT06665217 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07899398 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaRecruiting
Est. primary completion 2029-01-31 · NCT06859008 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-03 · NCT06350318 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2029-03-01 · NCT07548255 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2029-04 · NCT06167785 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-04 · NCT07739459 · CT.gov ↗
What to watch
May 2029 (2)
Phase 3Splenic Marginal Zone LymphomaActive not recruiting
Est. primary completion 2029-05 · NCT05735834 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-05-31 · NCT07594899 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-06-30 · NCT07717177 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2029-07-31 · NCT06846463 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-11-01 · NCT06854003 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-11-30 · NCT06697184 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2029-12 · NCT06664411 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-12-01 · NCT05890352 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07341191 · CT.gov ↗
What to watch
Phase 2BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT06890585 · CT.gov ↗
What to watch
Phase 2CLL / SLLNot yet recruiting
Est. primary completion 2029-12-31 · NCT07682415 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2030-02-28 · NCT06367374 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2030-03-01 · NCT06563596 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2030-03-23 · NCT07505849 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1CNS LymphomaRecruiting
Est. primary completion 2030-04-30 · NCT06730542 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2030-07-30 · NCT06503263 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-02 · NCT07277231 · CT.gov ↗
What to watch
March 2031 (1)
Phase 2Anti-MAG IgM-associated Demyelinating PolyneuropathyRecruiting
Est. primary completion 2031-03 · NCT07392229 · CT.gov ↗
What to watch
April 2031 (1)
Early phase / not applicableMarginal Zone Lymphoma(MZL)Not yet recruiting
Est. primary completion 2031-04-30 · NCT07299331 · CT.gov ↗
What to watch
2032 (3)
January 2032 (1)
Phase 1Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-01 · NCT06824701 · CT.gov ↗
What to watch
February 2032 (1)
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2032-02 · NCT06073821 · CT.gov ↗
What to watch
May 2032 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2032-05-31 · NCT06544785 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
Phase 2Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma …Not yet recruiting
Est. primary completion 2034-04-03 · NCT07638722 · CT.gov ↗
What to watch
2036 (1)
December 2036 (1)
Phase 4Waldenstrom Macroglobulinaemia, Multiple MyelomaNot yet recruiting
Est. primary completion 2036-12 · NCT07474961 · CT.gov ↗
What to watch
2038 (1)
August 2038 (1)
Phase 3Mantle Cell LymphomaRecruiting
Est. primary completion 2038-08-31 · NCT05976763 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026Topline resultZanubrutinib plus rituximab Phase 3 MANGROVE (NCT04002297) in untreated mantle cell lymphoma: positive topline results
BeOne Medicines Ltd. · Source ↗